MRD negativity after ASCT does not fully overcome the adverse prognostic impact of high-risk cytogenetics. Our latest publication on @LeukemiaJnl @ZanwarSaurabh @myelomaMD @VincentRK @ADispenzieri @Taxkourel @JoselleCookMD @MyelomaDrKapoor @YiLinMDPhD @MorieGertz
Estefania Gauto Mariotti, MD
@stefigm
BMT/plasma cell dyscrasias advanced fellowship. My views are my own.
485 Following 246 Followers 322 Posts
Latest posts 5
Fixed duration maintenance in standard-risk NDMM not undergoing up-front autologous transplant. Practice changing! Amazing Mayo experts I had the pleasure to learn from 😇
Just out!! In @NEJM - Our randomized trial in myeloma (ENDURANCE trial) shows limited duration of lenalidomide maintenance is just as good as indefinite therapy, with less side effects!!! @eaonc @theNCIView quoted post on X
Implications are HUGE. This is a drug we spends billions on each year:
-Less side effects
-Less second cancers
-Similar overall survival
-Less cost
@myelomaMD @Myeloma_Doc @SagarLonialMD
National NCI funded trial led by @eaonc and joined by @ALLIANCE_org & @SWOG
nejm.org/doi/full/10.10…
rdcu.be/fuSKW hot off the press! A wonderful way to wrap up my Dysproteinemia year at Mayo learning from world experts in myeloma. So grateful to all my coauthors, and a special thank you to Dr @ZanwarSaurabh and Dr Kumar @myelomaMD for their mentorship!
As response-adapted myeloma trials increasingly use early MRD negativity to guide treatment randomization and possible de-escalation, a key question is:View quoted post on X
Does MRD negativity after ASCT overcome the adverse biology of high-risk cytogenetics?
Our latest @LeukemiaJnl study suggests not necessarily.
Take-home message:
👉 MRD negativity after ASCT does not fully overcome the adverse prognostic impact of high-risk cytogenetics.
nature.com/articles/s4137…
Excellent work @Kennethjclim
This paper is a great read and addresses an area of uncertainty in #MyelomaView quoted post on X
Should we consider treating SBPmm with HR CG (del17p, 1q) like Myeloma? @Rfonsi1 @RahulBanerjeeMD @VincentRK @brandon_imber
A multi-center study of progression-risk and outcomes in solitary bone plasmacytoma with and without marrow involvement ashpublications.org/bloodadvances/…
A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance - PubMed pubmed.ncbi.nlm.nih.gov/41329731/?utm_…